Ana Alcaraz-Sanabria
Overview
Explore the profile of Ana Alcaraz-Sanabria including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Noblejas-Lopez M, Tebar-Garcia D, Lopez-Rosa R, Alcaraz-Sanabria A, Cristobal-Cueto P, Pinedo-Serrano A, et al.
Pharmaceutics
. 2023 Oct;
15(10).
PMID: 37896202
Targeted protein degradation has emerged as an alternative therapy against cancer, offering several advantages over traditional inhibitors. The new degrader drugs provide different therapeutic strategies: they could cross the phospholipid...
2.
Alcaraz-Sanabria A, Morafraile E, Fernandez-Hinojal G, Velasco G, Perez-Segura P, Pandiella A, et al.
Front Immunol
. 2022 Feb;
12:786069.
PMID: 35178045
Targeting K-RAS-mutant non-small cell lung cancer (NSCLC) with novel inhibitors has shown promising results with the recent approval of sotorasib in this indication. However, progression to this agent is expected,...
3.
Nieto-Jimenez C, Alcaraz-Sanabria A, Martinez-Canales S, Corrales-Sanchez V, Carlos Montero J, Burgos M, et al.
Int J Mol Sci
. 2020 Dec;
21(23).
PMID: 33261142
Basal-like breast cancer is an incurable disease with limited therapeutic options, mainly due to the frequent development of anti-cancer drug resistance. Therefore, identification of druggable targets to improve current therapies...
4.
Alcaraz-Sanabria A, Baliu-Pique M, Saiz-Ladera C, Rojas K, Manzano A, Marquina G, et al.
Front Oncol
. 2020 Jan;
9:1486.
PMID: 31998644
There is an unmet need for new therapies in metastatic ovarian cancer and basal-like breast cancer since no curative therapies are currently available. Immunotherapy has shown to be active in...
5.
Santpere G, Alcaraz-Sanabria A, Corrales-Sanchez V, Pandiella A, Gyorffy B, Ocana A
Oncotarget
. 2018 Feb;
9(1):453-463.
PMID: 29416627
In breast cancer, it is unclear the functional modifications at a transcriptomic level that are associated with the evolution from epithelial cells and ductal carcinoma (DCIS) to basal-like tumors. By...
6.
Nieto-Jimenez C, Alcaraz-Sanabria A, Paez R, Perez-Pena J, Corrales-Sanchez V, Pandiella A, et al.
Oncotarget
. 2017 Oct;
8(38):62834-62841.
PMID: 28968952
Background: Control of DNA damage is frequently deregulated in solid tumors. Upregulation of genes within this process can be indicative of a more aggressive phenotype and linked with worse outcome....
7.
Alcaraz-Sanabria A, Nieto-Jimenez C, Corrales-Sanchez V, Serrano-Oviedo L, Andres-Pretel F, Carlos Montero J, et al.
Mol Cancer Ther
. 2017 Aug;
16(11):2552-2562.
PMID: 28847989
Ovarian cancer is characterized by frequent mutations at TP53. These tumors also harbor germline mutations at homologous recombination repair genes, so they rely on DNA-damage checkpoint proteins, like the checkpoint...
8.
Perez-Pena J, Alcaraz-Sanabria A, Nieto-Jimenez C, Paez R, Corrales-Sanchez V, Serrano-Oviedo L, et al.
Oncotarget
. 2017 Apr;
8(13):21733-21740.
PMID: 28423514
Luminal breast tumors have been classified into A and B subgroups, with the luminal A being associated with a more favorable clinical outcome. Unfortunately, luminal A tumors do not have...
9.
Nieto-Jimenez C, Alcaraz-Sanabria A, Perez-Pena J, Corrales-Sanchez V, Serrano-Heras G, Galan-Moya E, et al.
Oncotarget
. 2017 Jan;
8(12):19478-19490.
PMID: 28061448
Metastatic triple negative breast cancer (TNBC) is an incurable disease with limited therapeutic options, and no targeted therapies available. Triple negative tumors and the basal-like genomic subtype, are both characterized...
10.
Ocana A, Perez-Pena J, Alcaraz-Sanabria A, Sanchez-Corrales V, Nieto-Jimenez C, Templeton A, et al.
Oncotarget
. 2016 Mar;
7(16):22865-72.
PMID: 26992217
Introduction: Accurate assessment of prognosis in early stage ovarian cancer is challenging resulting in suboptimal selection of patients for adjuvant therapy. The identification of predictive markers for cytotoxic chemotherapy is...